Here are the latest G-BA decisions from the G-BA meeting held on 5 June 2025 on the early benefit assessments of Elahere, Kisqali, and Yselty.
A complete database of all previous G-BA resolutions is in my membership.
- Elahere (mirvetuximab soravtansine); 0varian cancer, fallopian tube cancer, or primary peritoneal cancer, FRα-positive, platinum-resistant, after 1 to 3 prior therapies – Orphan drug, Indication of considerable additional benefit
- Kisqali (ribociclib); new indication: breast cancer, HR+, HER2-, early with high risk of recurrence, adjuvant therapy, combination with aromatase inhibitor – Additional benefit not proven across all 3 subgroups
- Yselty (linzagolix); new indication: endometriosis – Additional benefit not proven
- Amtagvi (lifileucel); melanoma – Request for RWE data collection and restriction of prescribing
- Columvi (glofitamab); relapsed or refractory diffuse large B-cell lymphoma – Termination of request for RWE data collection and restriction of prescribing, since the conditional EMA approval was changed to full approval
Follow me on Instagram to never miss the latest G-BA decisions:
